{"id":258648,"date":"2026-05-28T09:58:21","date_gmt":"2026-05-28T09:58:21","guid":{"rendered":"https:\/\/www.europesays.com\/se\/258648\/"},"modified":"2026-05-28T09:58:21","modified_gmt":"2026-05-28T09:58:21","slug":"dicot-pharma-har-ingatt-nya-avsiktsforklaringar-kopplat-till-sin-emission-nu-sakerstalld-till-80-procent","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/258648\/","title":{"rendered":"Dicot Pharma har ing\u00e5tt nya avsiktsf\u00f6rklaringar kopplat till sin emission &#8211; nu s\u00e4kerst\u00e4lld till 80 procent"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Forskningsbolaget Dicot Pharma har erh\u00e5llit avsiktsf\u00f6rklaringar fr\u00e5n befintliga aktie\u00e4gare om cirka 15,6 miljoner kronor i den p\u00e5g\u00e5ende f\u00f6retr\u00e4desemissionen. Det motsvarar cirka 7,4 procent av emissionen.\n <\/p>\n<p>Sedan tidigare finns teckningsf\u00f6rbindelser om cirka 33,3 miljoner kronor samt garanti\u00e5taganden p\u00e5 cirka 150,5 miljoner kronor. Totalt \u00e4r emissionen d\u00e4rmed s\u00e4kerst\u00e4lld till cirka 80 procent. Bolaget uppger att kapitalet ska finansiera en planerad fas 2b-studie.<br \/>\n <br class=\"col-start-2\"\/><\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">newsroom@finwire.se<br \/>\n <br class=\"col-start-2\"\/><br \/>\n Nyhetsbyr\u00e5n Finwire<\/p>\n","protected":false},"excerpt":{"rendered":"Forskningsbolaget Dicot Pharma har erh\u00e5llit avsiktsf\u00f6rklaringar fr\u00e5n befintliga aktie\u00e4gare om cirka 15,6 miljoner kronor i den p\u00e5g\u00e5ende f\u00f6retr\u00e4desemissionen.&hellip;\n","protected":false},"author":2,"featured_media":258649,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[72,5842,70,71,34,31,33,32,30],"class_list":["post-258648","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-business","tag-dicot-pharma","tag-economy","tag-ekonomi","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116651616286600484","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/258648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=258648"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/258648\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/258649"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=258648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=258648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=258648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}